Please select the eligibility criteria that correspond to the clinical trial below.
Title: Evaluation of the Efficacy and Safety of Fosfomycin Plus Imipenem for the Treatment of Methicillin-resistant Staphylococcus Aureus (MRSA) Infective Endocarditis.
Brief Summary: The study evaluates the efficacy and safety of fosfomycin and imipenem for the treatment of methicillin-resistant staphyloccocus aureus infective endocarditis in comparison to vancomycin, the standard therapy.


Options:
A: Inclusion Criteria:

* Suspected methicillin-resistant staphyloccocus aureus infective endocarditis on a native valve, prosthetic valve or pacemakers´s electrode or defibrillators with definitive or probable diagnosis by the modified Duke criteria (Li J, et al. Clin Infect Dis. 2000).
* Patients over 18 years.

Exclusion Criteria:

* Patients who did not sign informed consent.
* Patients with active consumption intravenous drug.
* Patients with emergent surgery criteria (\<72 hours).
* Patients or cardiogenic shock.
* Patients with antibiotic active against MRSA over 72 hours or they may need another antibiotic active against MRSA than those in the study.
* Patients with chronic renal failure on hemodialysis who received empirical treatment with vancomycin as a single dose and have a valley ≥ 15 mcg / mL on the third day.
* Patients with MRSA strains resistant to fosfomycin (MIC\> 64 mg / L) (\<10%) or vancomycin (MIC\> 2 mg / L) or with an MIC to vancomycin of 2 mg / L.
* Patients with any formal contraindication to be treated with study drugs
* Patients treated with any investigational drug within 30 days prior to entering the study.
B: Inclusion Criteria:

* Patients who underwent transcatheter (TAVI) or surgical aortic valve replacement (SAVR) for severe aortic valve stenosis
* Patients aged \>18 years
* Primary aortic valve procedure with a bioprosthesis for AS with or without associated regurgitation.
* TAVI and SAVR with or without associated coronary revascularization
* TAVI and SAVR for AS after any prior major cardiac surgery with exception of any maze procedure and/or closure of the left atrial appendage.

Exclusion Criteria:

* Patients who underwent any prior SAVR or TAVI
* Patients undergoing concomitant procedures on the mitral valve, tricuspid valve or the ascending aorta.
* Patients operated on for aortic valve endocarditis
* Patients operated for isolated aortic valve regurgitation.
C: Inclusion Criteria:

* Documented S. aureus bacteremia within 2 calendar days of the first dose of study medication

Exclusion Criteria:

* Subjects with a creatinine clearance of less than 30 ml/min
* Subjects with pneumonia
* Pregnant, nursing, or lactating
* Documented history of allergy or intolerance to penicillin or vancomycin
* Subjects with osteomyelitis
D: Inclusion Criteria:

* Left-sided endocarditis based on the Duke criteria
* Infected with one of the following microorganisms:

  * Streptococci
  * Enterococcus faecalis
  * Staphylococcus aureus
  * Coagulase-negative staphylococci.
* ≥ 18 years
* At least 10 days of appropriate parenteral antibiotic treatment overall, and at least 1 week of appropriate parenteral treatment after valve surgery
* Afebrile (T \< 38.0) \> 2 days
* Decreasing infection parameters (CRP dropped to less than 25% of peak value or \< 20 mg/l, and white blood cell count \< 15 x 109/l) during antibiotic treatment
* No sign of abscess formation by echocardiography
* Transthoracic and transoesophageal echocardiography performed within 48 hours prior to randomization

Exclusion Criteria:

* Body mass index \> 40
* Concomitant infection requiring intravenous antibiotic therapy
* Inability to give informed consent to participation
* Suspicion of reduced absorption of oral treatment due to abdominal disorder
* Reduced compliance

Answer: A